#1 Clinical Trials Search in Europe

Other Emollients And Protectives

This article discusses the use of “Other Emollients and Protectives” in clinical trials for treating atopic dermatitis. These trials aim to evaluate the safety and effectiveness of new treatments for moderate to severe atopic dermatitis in adults. The focus is on understanding how these emollients and protectives may help manage symptoms and improve the quality of life for patients with this chronic skin condition.

Table of Contents

What are OTHER EMOLLIENTS AND PROTECTIVES?

OTHER EMOLLIENTS AND PROTECTIVES refer to a group of topical treatments used to moisturize and protect the skin[1]. These products are designed to help manage various skin conditions, particularly those characterized by dryness, itching, and inflammation. In the context of this article, we’ll be focusing on their potential use in treating atopic dermatitis, also known as eczema.

Atopic Dermatitis: The Target Condition

Atopic dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin[1]. It’s a type of eczema that can significantly impact a person’s quality of life. The condition often requires ongoing management and treatment to control symptoms and prevent flare-ups.

Clinical Trial Information

A clinical trial is currently being conducted to evaluate a new treatment for moderate-to-severe atopic dermatitis in adults[1]. While the main focus of the trial is on a drug called LY3454738, it’s important to note that OTHER EMOLLIENTS AND PROTECTIVES are also being studied as part of the treatment regimen.

The trial aims to compare the effectiveness of the new treatment against a placebo. The main goal is to see if the treatment can significantly improve the symptoms of atopic dermatitis, as measured by a scale called the Eczema Area and Severity Index (EASI)[1]. Specifically, they’re looking at how many participants can achieve a 75% improvement in their EASI score, which is referred to as EASI-75.

Eligibility Criteria for the Study

To participate in this study, patients need to meet certain criteria[1]. These include:

  • Having active atopic dermatitis for over a year
  • Having a certain level of severity as measured by specific scales:
    • An EASI score of 12 or higher
    • A vIGA-AD score (another measure of severity) of 3 or higher
    • At least 10% of body surface area affected by atopic dermatitis
  • Having little improvement with topical medicines in the past

There are also conditions that would exclude someone from participating, such as:

  • Recent skin infections requiring treatment with topical corticosteroids
  • A history of psoriasis (another skin condition)
  • Certain other infections like Hepatitis B or C
  • Known allergies to the study drug or its components

Treatment Details

The OTHER EMOLLIENTS AND PROTECTIVES used in this study are applied topically, meaning they are put directly on the skin[1]. They are classified as “chemical” products, which means they are synthetically produced rather than derived from natural sources.

The exact dosage and frequency of application are not specified in the provided information. However, it’s noted that the maximum treatment period is set at 1 week[1]. This could mean that the emollients and protectives are used as part of a short-term treatment plan, possibly in conjunction with other medications being studied.

Potential Benefits and Considerations

Emollients and protectives are generally used to moisturize and protect the skin, which can be particularly beneficial for people with atopic dermatitis[1]. They may help to:

  • Reduce skin dryness
  • Alleviate itching
  • Improve the skin’s barrier function
  • Potentially reduce the need for other medications like topical corticosteroids

However, it’s important to note that this is an investigational treatment. The full effects and potential side effects are still being studied. As with any medical treatment, it’s crucial to discuss the potential benefits and risks with a healthcare provider.

Aspect Details
Study Type Phase 2, Randomized, Double-Blind, Placebo-Controlled
Duration 52 weeks
Condition Moderate-to-Severe Atopic Dermatitis
Main Objective Compare efficacy of LY3454738 vs placebo using EASI-75
Key Inclusion Criteria Active atopic dermatitis for over a year, EASI score ≥ 12, vIGA-AD score ≥3, ≥10% BSA involvement
Key Exclusion Criteria Prior skin infections requiring topical corticosteroids, history of psoriasis, certain infections
Treatment Category Other Emollients and Protectives
Administration Route Topical

FAQ

  • What is atopic dermatitis? Atopic dermatitis is a chronic skin condition characterized by itchy, inflamed skin. It's a type of eczema that can persist for over a year and may require various treatments to manage symptoms.
  • What are 'Other Emollients and Protectives'? 'Other Emollients and Protectives' refer to a category of topical treatments used to moisturize and protect the skin. In the context of atopic dermatitis, they may help soothe irritated skin and maintain skin barrier function.
  • How is the effectiveness of the treatment measured in these trials? The main measure of effectiveness in these trials is the EASI-75 score, which stands for Eczema Area and Severity Index. It indicates a 75% improvement in the severity and extent of atopic dermatitis symptoms.
  • Who can participate in these clinical trials? Participants must have active atopic dermatitis for over a year, meet specific severity criteria (such as an EASI score ≥ 12), and have shown little improvement with topical medicines. Some exclusions apply, such as having psoriasis or certain infections.
  • How long do these clinical trials last? Based on the information provided, one of the studies mentioned is a 52-week (1 year) study to evaluate the efficacy and safety of a specific treatment for atopic dermatitis.

Ongoing Clinical Trials on Other Emollients And Protectives

  • Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Hungary Italy Poland

Glossary

  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin. It's a type of eczema that can persist for extended periods.
  • EASI: Eczema Area and Severity Index, a tool used to measure the extent and severity of atopic dermatitis.
  • EASI-75: A score indicating a 75% improvement in the Eczema Area and Severity Index, used to measure treatment effectiveness.
  • vIGA-AD: Validated Investigator Global Assessment for Atopic Dermatitis, a scale used to assess the severity of atopic dermatitis.
  • BSA: Body Surface Area, used to measure the extent of skin affected by atopic dermatitis.
  • Emollients: Moisturizing treatments that help to soothe and hydrate the skin, often used in managing atopic dermatitis.
  • Topical: Referring to medications or treatments applied directly to the skin.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a new treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-ly3454738-for-treating-moderate-to-severe-atopic-dermatitis-in-adults/